NEXstar afoul of promotion police

NeXstar afoul of promotion police NeXstar Pharmaceuticals Inc. has been forced to withdraw promotional materials for its DaunoXome cancer drug following receipt of a nine-page warning letter from the FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC). The company (NXTR, Boulder, Colo.) declined to release the promotional materials or comment on the issues listed in the Feb. 21 warning letter. Spokesperson Joe Alper stated that the incident "is between the company and the FDA." The FDA, however, provided the letter to BioCentury. According to the letter, NXTR's promotional literature and other materials for DaunoXome (liposomal encapsulated daunorubicin) "contain statements, suggestions, or implications that are false and/or

Read the full 1309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE